Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

• Published in: Pulmonary therapy Vol. 10; no. 1; pp. 85 - 107
• Main Authors: Kim, Nick H., Chin, Kelly M., McLaughlin, Vallerie V., DuBrock, Hilary, Restrepo-Jaramillo, Ricardo, Safdar, Zeenat, MacDonald, Gwen, Martin, Nicolas, Rosenberg, Daniel, Solonets, Maria, Channick, Richard
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2024; Adis, Springer Healthcare
• Subjects: Family Medicine; General Practice; Internal Medicine; Macitentan; Medicine; Medicine & Public Health; Original Research; Pharmacoeconomics and Health Outcomes; Pharmacotherapy; Pneumology/Respiratory System; Portopulmonary hypertension; Pulmonary arterial hypertension; Quality of Life Research; Real-world evidence; Macitentan; Pulmonary arterial hypertension; Portopulmonary hypertension; Real-world evidence
• ISSN: 2364-1754; 2364-1746; 2364-1746
• DOI: 10.1007/s41030-023-00251-x

Introduction Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are usually excluded from clinical trials. This analysis describes patient charac...